Regeneron Pharmaceuticals Inc REGN:NASDAQ

Last Price$403.45Cboe Closing Price as of 3:59PM ET 2/21/20
Cboe Real-Time Quotes
Today's Change+4.31(1.08%)
Bid (Size)$404.09 (6)
Ask (Size)$404.33 (1)
Day Low / High$393.39 - 404.54
Volume491.1 K

Regeneron Says REGN-EB3 Therapy Shows Superiority to ZMapp in Preventing Ebola Deaths

3:15PM ET 8/12/2019 MT Newswires
Regeneron Pharmaceuticals (REGN), a clinical stage biopharmaceutical company, said on Monday that a clinical trial evaluating four investigational therapies for Ebola virus infection was stopped early because REGN-EB3 was superior to ZMapp in preventing death.

The PALM trial was conducted in the Democratic Republic of Congo, where the current outbreak is ongoing. ZMapp served as the control arm of the trial. The investigators decided to stop the trial after reviewing interim mortality data from 499 patients, Regeneron said in a statement. The trial was first initiated last year with three treatment arms: mAb114, remdesivir and ZMapp.

"This trial is a remarkable advance in the decades-long struggle to respond to Ebola," Regeneron quoted leading investigator Dr. Sumathi Sivapalasingam as saying in the statement.

Meanwhile, the New York Times reported on Monday, citing Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, that the mortality rate in REGN-EB3 was 6%, compared to 24% in ZMapp, 11% in mAb114, and 33% in remdesivir.

Price: 297.48, Change: -7.41, Percent Change: -2.43